Medicated Skin Care in Norway
Medicated skin care increased by 2% in current value terms in 2011 to NOK254 million. Growth in 2011 was one percentage point lower than the CAGR for the review period. Competition from beauty care brands and price competition among retailers dampened growth.
Euromonitor International's Medicated Skin Care in Norway report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2007-2011, allowing you to identify the sectors driving growth. Forecasts to 2016 illustrate how the market is set to change.
Product coverage: Antiparasitics/Lice (Head and Body) Treatments, Antipruritics, Cold Sore Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals, Topical Germicidals/Antiseptics, Vaginal Antifungals.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
Euromonitor International's Medicated Skin Care in Norway report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2007-2011, allowing you to identify the sectors driving growth. Forecasts to 2016 illustrate how the market is set to change.
Product coverage: Antiparasitics/Lice (Head and Body) Treatments, Antipruritics, Cold Sore Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals, Topical Germicidals/Antiseptics, Vaginal Antifungals.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
- Get a detailed picture of the Medicated Skin Care market;
- Pinpoint growth sectors and identify factors driving change;
- Understand the competitive environment, the market’s major players and leading brands;
- Use five-year forecasts to assess how the market is predicted to develop.
MEDICATED SKIN CARE IN NORWAY
Euromonitor International
June 2012
LIST OF CONTENTS AND TABLES
Headlines
Trends
Switches
Competitive Landscape
Prospects
Category Data
Table 1 Sales of Medicated Skin Care by Category: Value 2006-2011
Table 2 Sales of Medicated Skin Care by Category: % Value Growth 2006-2011
Table 3 Medicated Skin Care Company Shares by Value 2007-2011
Table 4 Medicated Skin Care Brand Shares by Value 2008-2011
Table 5 Hair Loss Treatments Brand Shares by Value 2008-2011
Table 6 Forecast Sales of Medicated Skin Care by Category: Value 2011-2016
Table 7 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2011-2016
Nycomed Pharma As in Consumer Health (norway)
Strategic Direction
Key Facts
Summary 1 Nycomed Pharma AS: Key Facts
Summary 2 Nycomed Pharma AS: Operational Indicators
Company Background
Production
Summary 3 Nycomed Pharma AS: Production Statistics 2011
Competitive Positioning
Summary 4 Nycomed Pharma AS: Competitive Position 2011
Weifa As in Consumer Health (norway)
Strategic Direction
Key Facts
Summary 5 Weifa AS: Key Facts
Summary 6 Weifa AS: Operational Indicators
Company Background
Production
Summary 7 Weifa AS: Production 2011
Competitive Positioning
Summary 8 Weifa AS: Competitive Position 2011
Executive Summary
Stable Growth in Value Sales for 2011
Prudent Spending Habits Emerge
Global Players Drive Competition
Important Role for Non-store Retailing
Moderate Increase Predicted
Key Trends and Developments
Consumption Declines in Spite of Rising Disposable Household Income
Multinationals Have A Bigger Role in Norway
Greater Access To Internet Adds A New Dimension To Marketing Consumer Health Products
New Products for An Ageing Population
Government-led Health Initiatives
Market Indicators
Table 8 Consumer Expenditure on Health Goods and Medical Services 2006-2011
Table 9 Life Expectancy at Birth 2006-2011
Market Data
Table 10 Sales of Consumer Health by Category: Value 2006-2011
Table 11 Sales of Consumer Health by Category: % Value Growth 2006-2011
Table 12 Consumer Health Company Shares 2007-2011
Table 13 Consumer Health Brand Shares 2008-2011
Table 14 Penetration of Private Label by Category 2006-2011
Table 15 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
Table 16 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
Table 17 Forecast Sales of Consumer Health by Category: Value 2011-2016
Table 18 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016
Appendix
OTC Registration and Classification
De-listing Or De-reimbursement
Bioequivalent/generics
Combination Products
Advertising
Packaging
Labelling
Distribution
Vitamins and Dietary Supplements Registration and Classification
Self-medication/self-care and Preventative Medicine
Switches
Summary 9 OTC - Switches 2009-2011
Definitions
Sources
Summary 10 Research Sources
Euromonitor International
June 2012
LIST OF CONTENTS AND TABLES
Headlines
Trends
Switches
Competitive Landscape
Prospects
Category Data
Table 1 Sales of Medicated Skin Care by Category: Value 2006-2011
Table 2 Sales of Medicated Skin Care by Category: % Value Growth 2006-2011
Table 3 Medicated Skin Care Company Shares by Value 2007-2011
Table 4 Medicated Skin Care Brand Shares by Value 2008-2011
Table 5 Hair Loss Treatments Brand Shares by Value 2008-2011
Table 6 Forecast Sales of Medicated Skin Care by Category: Value 2011-2016
Table 7 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2011-2016
Nycomed Pharma As in Consumer Health (norway)
Strategic Direction
Key Facts
Summary 1 Nycomed Pharma AS: Key Facts
Summary 2 Nycomed Pharma AS: Operational Indicators
Company Background
Production
Summary 3 Nycomed Pharma AS: Production Statistics 2011
Competitive Positioning
Summary 4 Nycomed Pharma AS: Competitive Position 2011
Weifa As in Consumer Health (norway)
Strategic Direction
Key Facts
Summary 5 Weifa AS: Key Facts
Summary 6 Weifa AS: Operational Indicators
Company Background
Production
Summary 7 Weifa AS: Production 2011
Competitive Positioning
Summary 8 Weifa AS: Competitive Position 2011
Executive Summary
Stable Growth in Value Sales for 2011
Prudent Spending Habits Emerge
Global Players Drive Competition
Important Role for Non-store Retailing
Moderate Increase Predicted
Key Trends and Developments
Consumption Declines in Spite of Rising Disposable Household Income
Multinationals Have A Bigger Role in Norway
Greater Access To Internet Adds A New Dimension To Marketing Consumer Health Products
New Products for An Ageing Population
Government-led Health Initiatives
Market Indicators
Table 8 Consumer Expenditure on Health Goods and Medical Services 2006-2011
Table 9 Life Expectancy at Birth 2006-2011
Market Data
Table 10 Sales of Consumer Health by Category: Value 2006-2011
Table 11 Sales of Consumer Health by Category: % Value Growth 2006-2011
Table 12 Consumer Health Company Shares 2007-2011
Table 13 Consumer Health Brand Shares 2008-2011
Table 14 Penetration of Private Label by Category 2006-2011
Table 15 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
Table 16 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
Table 17 Forecast Sales of Consumer Health by Category: Value 2011-2016
Table 18 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016
Appendix
OTC Registration and Classification
De-listing Or De-reimbursement
Bioequivalent/generics
Combination Products
Advertising
Packaging
Labelling
Distribution
Vitamins and Dietary Supplements Registration and Classification
Self-medication/self-care and Preventative Medicine
Switches
Summary 9 OTC - Switches 2009-2011
Definitions
Sources
Summary 10 Research Sources